Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.

29 Jul 2014

Research points to new direction for potential therapies to treat mucoepidermoid carcinoma

Research conducted at the Florida campus of The Scripps Research Institute has discovered links between a set of genes known to promote tumor growth and mucoepidermoid carcinoma, an oral cancer that affects the salivary glands. The discovery could help physicians develop new treatments that target the cancer's underlying genetic causes.

29 Jul 2014

Researchers provide global genotype prevalence estimates for HCV

In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia.

28 Jul 2014

Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Clinicians and researchers from Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University will present new findings from eight abstracts at the International Federation of Head and Neck Oncologic Societies World Congress being held July 26 - July 30 in New York.

26 Jul 2014

Genticel provides update on patents granted in the USA and Asia

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, provides an update on patents that have recently enriched its intellectual property estate.

25 Jul 2014

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

25 Jul 2014

Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found.

24 Jul 2014

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

23 Jul 2014

Cytoreductive nephrectomy can benefit patients with mRCC

Patients treated with targeted therapy for metastatic renal cell carcinoma may derive significant survival benefit from cytoreductive nephrectomy, particularly if their initial prognosis is good, study findings indicate.

22 Jul 2014

Marker identified for population of renal cancer cells with stem-cell-like features

Researchers have identified a population of clear cell renal cell carcinoma cells positive for the CTR2 marker that possess some stem-cell-like features and are able to induce an angiogenic response in vivo.

22 Jul 2014

Partial nephrectomy retains edge over radical nephrectomy in larger renal tumors

Patients with renal cell carcinoma tumours larger than 4 cm benefit from undergoing elective partial nephrectomy rather than radical nephrectomy surgery, a study has found.

22 Jul 2014

Alternative sunitinib treatment schedules for mRCC may be worth the switch

Some patients with metastatic renal cell carcinoma who are switched from a traditional sunitinib treatment schedule to an alternative schedule fare better on survival measures and suffer fewer adverse events, a Japanese study has found.

22 Jul 2014

Marker identified for population of renal cancer cells with stem-cell-like features

22 Jul 2014

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

There is considerable crosstalk between the CXCR4–CXCL12–CXCR7 axis and the mammalian target of rapamycin pathway in human renal cell carcinoma, and targeting the axis may overcome drug resistance to mTOR inhibitors, researchers suggest.

22 Jul 2014

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that China's Food and Drug Administration has approved the Company's application to conduct a Phase II clinical trial in triple-negative breast cancer (TNBC) patients in China for its proprietary drug candidate, ENMD-2076.

21 Jul 2014

A personalized approach for patients with ccRCC-related mutations

In an analysis of small molecules called metabolites used by the body to make fuel in normal and cancerous cells in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth.

21 Jul 2014

TAZ represents a novel therapeutic target in NSCLC

Patients with non-small-cell lung cancer who express high levels of transcriptional coactivator with PDZ-binding motif may be a clinically distinct subgroup with an unfavourable prognosis, researchers report.

16 Jul 2014

CIP2A pathway involved in erlotinib response

Researchers have identified a novel mechanism, involving the cancerous inhibitor of protein phosphatase 2A pathway, which mediates the anti-tumour effects of erlotinib in non-small-cell lung cancer cells without epidermal growth factor receptor mutations.

16 Jul 2014

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014

Tamoxifen gel stops breast cancer growth without causing dangerous side effects

A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects that deter some women from taking it, according to new Northwestern Medicine- research.

16 Jul 2014

Carcinoma News and Research

Further Reading

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

Research points to new direction for potential therapies to treat mucoepidermoid carcinoma

Researchers provide global genotype prevalence estimates for HCV

Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Genticel provides update on patents granted in the USA and Asia

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Advaxis, MedImmune team up for immuno-oncology clinical trial

Cytoreductive nephrectomy can benefit patients with mRCC

Marker identified for population of renal cancer cells with stem-cell-like features

Partial nephrectomy retains edge over radical nephrectomy in larger renal tumors

Alternative sunitinib treatment schedules for mRCC may be worth the switch

Marker identified for population of renal cancer cells with stem-cell-like features

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

A personalized approach for patients with ccRCC-related mutations

TAZ represents a novel therapeutic target in NSCLC

CIP2A pathway involved in erlotinib response

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

Tamoxifen gel stops breast cancer growth without causing dangerous side effects

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News